Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 101 - 150 av 151 resultater
Tid
Selskap
Tittel
Sektor
Kategori
15 Dec 2021
07:01 CET
CELYAD ONCOLOGY
Notification de Transparence de Fortress Investment Group LLC (Article 14§1 de la loi du 2 mai 2007)
20103010 Biotechnology
Other subject
15 Dec 2021
07:01 CET
CELYAD ONCOLOGY
Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
20103010 Biotechnology
Other subject
13 Dec 2021
07:01 CET
CELYAD ONCOLOGY
Celyad Oncology présente des mises à jour sur les programmes CAR-T basés sur la technologie ARNsh lors de la 63e assemblée et exposition annuelles de l’ASH
20103010 Biotechnology
Other subject
13 Dec 2021
07:01 CET
CELYAD ONCOLOGY
Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition
20103010 Biotechnology
Other subject
08 Dec 2021
22:02 CET
CELYAD ONCOLOGY
Celyad Oncology annonce la clôture du placement privé de 32,5 millions USD souscrit par une filiale de Fortress Investment Group
20103010 Biotechnology
Other financial transaction
08 Dec 2021
22:02 CET
CELYAD ONCOLOGY
Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate
20103010 Biotechnology
Other financial transaction
03 Dec 2021
07:31 CET
CELYAD ONCOLOGY
Celyad Oncology annonce un placement privé de 32,5 millions de dollars souscrit par Fortress Investment Group
20103010 Biotechnology
Other financial transaction
03 Dec 2021
07:31 CET
CELYAD ONCOLOGY
Celyad Oncology Announces $32.5 Million Private Placement With Fortress Investment Group
20103010 Biotechnology
Other financial transaction
12 Nov 2021
13:00 CET
CELYAD ONCOLOGY
Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
20103010 Biotechnology
Other subject
12 Nov 2021
13:00 CET
CELYAD ONCOLOGY
Celyad Oncology présente des données précliniques sur le programme de thérapie allogénique CAR T et précise le concept de l'essai clinique KEYNOTE-B79 lors de la 36e réunion annuelle de la Society for Immunotherapy of Cancer (SITC)
20103010 Biotechnology
Other subject
10 Nov 2021
22:05 CET
CELYAD ONCOLOGY
Celyad Oncology publie ses résultats financiers du troisième trimestre 2021 et les avancées récentes des activités de la Société
20103010 Biotechnology
Other subject
10 Nov 2021
22:05 CET
CELYAD ONCOLOGY
Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights
20103010 Biotechnology
Other subject
04 Nov 2021
14:01 CET
CELYAD ONCOLOGY
Celyad Oncology présentera une mise à jour de ses programmes CAR T allogéniques et autologues lors du 63ème ASH Annual Meeting and Exposition
20103010 Biotechnology
Other subject
04 Nov 2021
14:01 CET
CELYAD ONCOLOGY
Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition
20103010 Biotechnology
Other subject
02 Nov 2021
08:00 CET
CELYAD ONCOLOGY
Celyad Oncology Announces November 2021 Conference Schedule
20103010 Biotechnology
Other subject
02 Nov 2021
08:00 CET
CELYAD ONCOLOGY
Celyad Oncology annonce sa participation à une Conférences en novembre 2021
20103010 Biotechnology
Other subject
29 Oct 2021
22:05 CEST
CELYAD ONCOLOGY
Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)
20103010 Biotechnology
Change in Capital
29 Oct 2021
22:05 CEST
CELYAD ONCOLOGY
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
20103010 Biotechnology
Change in Capital
01 Oct 2021
14:00 CEST
CELYAD ONCOLOGY
Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting
20103010 Biotechnology
New
01 Oct 2021
14:00 CEST
CELYAD ONCOLOGY
Celyad Oncology présentera de nouvelles données sur le programme de thérapie CAR T allogénique lors du Congrès Annuel de la Société d’Immunothérapie pour le Cancer (SITC)
20103010 Biotechnology
New
01 Sep 2021
09:24 CEST
CELYAD ONCOLOGY
CORRIGE ET REMPLACE : Celyad Oncology annonce sa participation à plusieurs Conférences en septembre 2021
20103010 Biotechnology
Other subject
01 Sep 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Announces September 2021 Conferences Schedule
20103010 Biotechnology
New
01 Sep 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology annonce sa participation à plusieurs Conférences en juin 2021
20103010 Biotechnology
New
04 Aug 2021
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
20103010 Biotechnology
New
04 Aug 2021
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology publie ses résultats financiers du premier semestre 2021 et les avancées récentes de la Société
20103010 Biotechnology
New
30 Jul 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)
20103010 Biotechnology
New
30 Jul 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
20103010 Biotechnology
New
29 Jul 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology annoncera prochainement les résultats financiers du premier semestre 2021 et tiendra une conférence téléphonique
20103010 Biotechnology
New
29 Jul 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call
20103010 Biotechnology
New
20 Jul 2021
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology Presenteert Updates over Allogene CAR T Klinische Kandidaten en shRNA-gebaseerde Preklinische Concepten op de Onderzoek&Ontwikkeling Dag
20103010 Biotechnology
Meetings / events
20 Jul 2021
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day
20103010 Biotechnology
Meetings / events
20 Jul 2021
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology présente des mises à jour sur ses candidats CAR T cliniques allogéniques et des concepts précliniques à base de shRNA lors de son Webinar R&D
20103010 Biotechnology
Meetings / events
13 Jul 2021
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology organisera un R&D Day virtuel le 20 juillet 2021
20103010 Biotechnology
New
13 Jul 2021
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology to Host Virtual Research & Development Webinar on July 20th
20103010 Biotechnology
New
07 Jul 2021
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology participera à la Conférence William Blair Biotech Focus 2021
20103010 Biotechnology
New
07 Jul 2021
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021
20103010 Biotechnology
New
30 Jun 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
20103010 Biotechnology
New
30 Jun 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)
20103010 Biotechnology
New
11 Jun 2021
08:59 CEST
CELYAD ONCOLOGY
Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
20103010 Biotechnology
New
11 Jun 2021
08:59 CEST
CELYAD ONCOLOGY
Celyad Oncology présente les données préliminaires de son essai de Phase 1 IMMUNICY-1 du candidat CAR T allogénique CYAD-211 basé sur la technologie shRNA...
20103010 Biotechnology
New
11 Jun 2021
08:59 CEST
CELYAD ONCOLOGY
Celyad Oncology Presenteert Preliminaire Data van Fase 1 IMMUNICY-1 Studie van shRNA-gebaseerde Allogene CAR T Kandidaat CYAD-211 in Hervallen/Refractair Multipel Myeloom op het European Hematology Association Virtueel Congres
20103010 Biotechnology
New
31 May 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)
20103010 Biotechnology
New
31 May 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
20103010 Biotechnology
New
26 May 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Announces June 2021 Conference Schedule
20103010 Biotechnology
New
26 May 2021
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology annonce sa participation à plusieurs Conférences en juin 2021
20103010 Biotechnology
New
19 May 2021
07:01 CEST
CELYAD ONCOLOGY
Celyad Oncology SA : Notification de Transparence de Victory Capital Management Inc. (Article 14§1 de la loi du 2 mai 2007)
20103010 Biotechnology
New
19 May 2021
07:01 CEST
CELYAD ONCOLOGY
Celyad Oncology SA: Transparency Notification Received From Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)
20103010 Biotechnology
New
12 May 2021
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology to Present Data From Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
20103010 Biotechnology
New
12 May 2021
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology présentera des données de l’essai de Phase 1 IMMUNICY-1 du candidat CAR T allogénique, ne faisant pas appel à l’édition de génome, CYAD-211 pour les patients atteints de r/r MM au Congrès Virtuel de l’EHA
20103010 Biotechnology
New
06 May 2021
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology publie ses Résultats Financiers du Premier Trimestre 2021 et les Avancées Récentes de la Société
20103010 Biotechnology
New
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva